Last reviewed · How we verify
Henagliflozin in Patients With Atrial Fibrillation (HENA-AF)
The HENA-AF trial will evaluate the effects of henagliflozin on cardiac structure, function, and biomarkers of HF in patients with AF. Participants with persistent AF, enlarged left atrium, and at least another cardiovascular risk factor will be randomized to henagliflozin or placebo. Cardiac MRI will be performed at baseline and at 6 months to measure the changes in cardiac structure and function. The primary hypothesis is that henagliflozin will reduce the left atrial volume index at 6 months in patients with AF.
Details
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Phase | PHASE3 |
| Status | UNKNOWN |
| Enrolment | 100 |
| Start date | Thu Sep 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Sep 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atrial Fibrillation
Interventions
- placebo
- Henagliflozin 5Mg Tab
Countries
China